

Review

Not peer-reviewed version

Translation of Circular RNAs

[Giorgi Margvelani](#) , Karol Andrea Arizaca Maquera , Justin Ralph Welden , David W Rodgers , [Stefan Stamm](#) *

Posted Date: 28 June 2024

doi: 10.20944/preprints202406.1968.v1

Keywords: circRNAs; Backsplicing; circRNAs translation; RNA modification



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Translation of Circular RNAs

Giorgi Margvelani [#], Karol Andrea Arizaca Maquera [#], Justin Ralph Welden, David W. Rodgers and Stefan Stamm ^{*}

University of Kentucky, Molecular and Cellular Biochemistry, 741 South Limestone, Lexington, KY 40503

^{*} Correspondence: stefan@stamms-lab.net

[#] Joined coauthors.

Abstract: Circular RNAs (circRNAs) are covalently closed RNAs that are present in all eukaryotes tested. CircRNAs are less abundantly expressed than mRNAs. Recent RNAseq analyses indicate that more than 800,000 circRNA isoforms exist in humans, which is more than twice the number of currently known mRNA isoforms. CircRNAs are generated through backsplicing that depends on pre-mRNA structures, which are influenced by intronic elements, for example primate-specific Alu elements, leading to species-specific circRNAs. CircRNAs are mostly cytosolic, stable and influence cells by sequestering miRNAs and RNA-binding proteins. We review the increasing evidence that circRNAs are translated into proteins using several cap-independent translational mechanisms, that include internal ribosomal entry sites, N6-methyladenosine RNA modification, adenosine to inosine RNA editing and interaction with the eIF4A3 component of the exon junction complex. CircRNA are translated under conditions that favor cap-independent translation, notably in cancer. CircRNA-encoded proteins are shorter than mRNA-encoded proteins and overall have a high propensity for phase separation. In summary, circRNA encoded proteins are translated under particular cellular conditions and contribute to proteome diversity and pathophysiology.

Keywords: circRNAs; Backsplicing; circRNAs translation; RNA modification

Introduction

Circular RNAs contribute considerably to transcriptome diversity.

Thirty-three years ago, RT-PCR analysis of the tumor suppressor gene DCC (Deleted in Colorectal Carcinoma) revealed the order of exons to be reversed in a small portion of mRNA. For example, for an RNA corresponding to a genomic clone with the order exon B - exon C - exon D, the orientation exon D to exon B was observed [1]. **It was later found that eukaryotic genes form circular RNAs (circRNA) using canonical splice sites [2,3],** which explained the scrambled arrangement. Early reports indicated that a circular RNA made from an archaea pre-23 rRNA is translated into an endonuclease of 194 amino acids [4]. **Technical progress in RNA sequencing showed then a widespread expression of circular RNAs that are present in all eukaryotes tested [5,6].**

Circular RNAs are covalently closed RNAs generated from pre-mRNA. They are less abundant than linear mRNAs, making it necessary to enrich them using rRNA removal and digestion of linear mRNA with RNase R, which is followed by next generation sequencing. This approach identifies the backsplice junction, which allows to predict the RNA structure based on the annotated exons. However, with this approach the sequence information outside the reads of the backsplice site remains unknown. Recently, rolling circle amplification of circular RNAs, followed by adaptor addition and long range nanopore sequencing allowed identification of full-length circular RNAs [7-9]. These circRNAs were collected in databases (**Table 1**). Together, sequencing efforts identified more than 880,000 backsplicing events in humans that potentially generate more than 1.8 million human circular RNA isoforms [10], which compares to about 320,000 human mRNA isoforms from annotated genes **and over 30 million transcripts from other human genomic loci [11], suggesting that circRNAs play a so far overlooked role in the eukaryotic transcriptome.**

Formation of circular RNAs through backsplicing that depends on intronic regions.

Circular RNAs are generated through backsplicing, where an upstream 5' splice site is connected to a downstream 3' splice site (Figure 1). These splice sites can be thousands of base pairs apart in the pre-mRNA, indicating that additional mechanisms are necessary to bring the backsplice sites into close vicinity. Pre-mRNAs secondary structures formed by complementary intronic sequences are likely a major contributor to circRNA formation [12]. The complementary sequences are often provided by repetitive elements, for example Alu-elements in primates or B1 elements in rodents. As these genomic elements are species-specific, they could contribute to the species-specificity found in some circRNAs.

Alu-elements are about 300 nt long repetitive elements and comprise 11% of the human genome [13]. RNA in situ conformation sequencing (RIC-seq) showed that Alu elements promoted more than 37% of all RNA-RNA interactions across enhancers [14]. It is likely that Alu elements play a similar prominent role in forming pre-mRNA structures, which is supported by the findings that in humans circRNA backsplice sites are often surrounded by Alu-elements and numerous circRNAs are human-specific [10]. Alu elements are similar to the 5' and 3' end of the 7SL RNA from which they originated but lack a 155 nt long 7SL-specific part. Alu elements consist of a left arm composed of a head to tail dimer of two similar sequences, each of which is about 130 nt long. Following a stretch of adenosines, the right Alu-arm contains an additional insert [15]. Reflecting the highly structured 7SL RNA, Alu-elements exhibit complementarity through direct RNA interactions, especially when present in a sense to antisense orientation in the pre-mRNA. Double stranded RNAs are the substrate of ADAR enzymes (adenosine deaminase acting on RNA) that change adenosines to inosines. In humans more than 99% of all edited RNAs are derived from Alu-elements [16,17], **demonstrating that intramolecular dsRNA regions formed by Alu-elements are common in pre-mRNAs.**




Figure 1. Generation of circRNAs through backsplicing. **Generation and overall functions of mRNAs and circRNAs A.** A pre-mRNA containing three exons and two introns flanking the central exon can be processed into a mRNA containing a 5' cap and a poly adenosine tail. mRNAs are predominantly exported by the TREX (transcription and RNA export) complex from the nucleus to the cytosol where they are translated. **B.** A small fraction of the pre-mRNA can undergo backsplicing when the 5' and 3' splice site are brought into

close proximity, which is promoted by RNA secondary structures or mediated by proteins. In humans, pre-mRNA structures are often introduced by Alu elements that form long complementary sequences, which are the major substrate for ADAR enzymes. CircRNAs are exported via an exportin-2 IGFBP2-RanGTP complex. In the cytosol they sequester miRNAs, RNA binding proteins or act as translational templates.

Mouse B1 elements are related to human Alu elements and are also derived from 7SL-RNA. However, B1 elements are more diverse and shorter (about 140 nt) than Alu elements, consisting of only one monomer, which likely decreases the preponderance of self-complementarity and overall RNA editing [18].

Back splicing can also be promoted by proteins. For example, the interaction between Alu-element RNA can be increased by SLU7 Homolog- Splicing Factor (SLU7) binding to the flanking Alu sequences of circCAPG, which promotes circRNA generation [19]. Protein dependent promotion of circRNA formation can occur without Alu elements, and more than 15 RNA-binding proteins were shown to promote circRNA formation, among them QKI [20], RBM20 [21], hnRNP L and FUS (reviewed in [24]).

Circular RNAs are cytosolic, more stable than mRNAs and use a nuclear-cytoplasmic export pathway different from mRNAs.

Due to their generation through backsplicing, circRNAs lack a 7-methyl guanosine cap at their 5' end (5' cap) and also do not have a poly A tail at their 3' end. CircRNAs collected in recent databases have an average (median) length of around 750 nt and about 20% of circRNAs are longer than 500 nt, with up to 81,000 nt in length. Circular RNAs almost always use exons that are already used by linear RNAs, i.e. are composed of exons annotated in the database [10].

The generation of circRNAs through backsplicing occurs in the nucleus. Once generated, circRNAs form a complex with insulin-like growth factor 2 mRNA-binding protein (IGF2BP1). This complex is exported into the cytosol through interaction with exportin 2 and Ran-GTP [25]. Thus, the circRNA export mechanism is distinct from mRNAs that use recognition of the exon-junction by the TREX (transcription export) complex for cytosolic export [26,27]. The nuclear-cytoplasmic distribution of circRNAs can be influenced by external stimuli. For example, hypoxia leads to a translocation of circLRP6 from the nucleus to the cytosol, possibly mediated by binding to hnRNP M that accumulates in the cytosol under hypoxic conditions [28].

The high stability of circRNAs is another striking difference between circular and mRNAs. Half-lives have been measured for several circRNAs, for example for circYAP1 [29], circTRCP [30], circARHGAP35 and circHER2 [32]. In cell-based assays circRNA half-lives were found to be longer than 24 hrs, which is the upper limit of detection, indicating that the true half-lives may be longer. **This compares to a global mRNA half-life of 4.3 hrs making circRNA exceptionally stable.**

Circular RNAs can sequester nucleic acids and proteins.

A) Interaction with nucleic acids

Despite the widespread expression of circRNAs, their biological functions are poorly understood. CircRNAs can sequester nucleic acids and proteins. Binding to miRNAs was the first function identified for circRNAs where the highly abundant circRNA ciRS-7/CDR1as binds to miR-7 and exerts biological effects through miR-7 sequestration ('sponging') [34], which has been found for many other circRNAs reviewed in [35,36]. Binding to DNA via base-pair interaction is also possible, for example in *Arabidopsis thaliana* the circular RNA made from exon 6 of the SEPALLATA3 gene binds to its own DNA locus, forming an R-loop of circRNA and DNA [37].

B) Binding to proteins

CircRNAs were shown to bind to numerous proteins, mainly RNA binding proteins, and computational predicted binding sites were collected in databases [38]. Sequestration of proteins by circRNAs can have numerous effect on transcription, cell cycle progression, apoptosis and cell migration (reviewed in [39]).

Evidence for translation of circular RNAs

Most circular RNAs contain open reading frames and initially over 4,000 circRNAs were predicted to encode proteins [40], that number has increased to more than 300,000 in the recent

transCirc database [41]. There is now an increasing number of studies showing translation of circular RNAs.

Early evidence that circRNAs can be translated came from studies in 1988 using the archaeobacterium *Desulfurococcus mobilis*, where an intron from the pre-23rRNA is excised as a stable circular RNA that encodes an endonuclease of 194 amino acids that can spread through other strains [4]. **In mammalian systems, exon 2 of circSLC8A1 (previously named NCX1) was shown in 1999 to encode a protein that transports calcium across a membrane [42]. Proof of principle studies in 1995 showed that circular RNAs can be translated in vitro if they contain internal ribosomal entry sites (IRES) [43], which has been confirmed for different IRESes [44]. Rolling circle translation has been observed even in chemically modified circRNAs containing phosphoramidate linkages [45]. However, the translational potential of cellular circular RNAs was controversial, as initial screens of circular RNAs with open reading frames did not detect translation [46]. Further studies validated the translation of a growing number of circular RNAs in physiological systems (Table 2). Evidence that circRNAs are translated comes from their association with polysomes, indicating active translation; validation of backsplice site-encoded peptides using mass-spectrometry and detection of circRNA encoded proteins using specific antisera.**

Association with polysomes

Over 3,000 publicly available Ribo-seq databases were analyzed for the presence of circRNAs, which identified 1,969 polysome associated circRNAs in six different species, which were collected in the riboCirc database **that expanded the previous transCirc database [41]. The polysome association was confirmed for numerous transcripts using RT-PCR of independent polysome preparations [48]. Similarly, numerous studies focusing on a defined circRNA showed polysome association, indicated in Table 2.**

Ribosome foot printing experiments showed a significant increase in circular RNAs when the polysomes were prepared in the presence of detergent (0.1% Triton), indicating that circRNA translating ribosomes are associated with membranes [49]. Since detergent is omitted in most polysome preparation protocols, the actual number of circRNAs associated with polysomes could be underestimated. Translation and polysome association of circular RNAs could be cell-type specific. For example, erythrocytes and platelets contain high levels of circRNAs, but only 32 circRNAs were polysome associated in erythroblasts [50].

Validation by Mass-spectrometry

The translation of several circRNAs was also confirmed by mass-spectrometry that detects a peptide corresponding to the backsplice junction. One of the first of these proteins was drosophila muscleblind [49], and subsequently backsplice site peptides of numerous human proteins were identified (Table 2). During sperm development, mRNAs are degraded in pachytene spermatocytes, leading to an enrichment of circular RNAs. Mass-spectrometry analysis using mouse testes identified over 1,600 peptides corresponding to backsplice junctions, indicating widespread circular RNA translation [51]. Analysis of human hearts showed 8,878 circular RNAs, of which 40 were associated with polysomes and mass-spectrometry evidence for translation was found for six of these proteins [52], showing translation of human circular RNAs in a differentiated tissue.

Detection of circRNA encoded proteins using specific antisera.

Proteins encoded by circRNAs often have specific amino and carboxy termini (Figure 2A), which makes it possible to generate circRNA-encoded protein specific antisera (Table 2). A common problem is that these circRNA-specific sequences shown in Supplemental Figure 1 are usually short, which can make it difficult to generate specific antisera.

Detection of circRNA encoded proteins using reporter genes.

Transfection studies with reporter genes were first used to prove the possibility of circRNA translation. Usually, these reporter genes contain a protein tag like a 3x flag tag that is located upstream of the start codon and thus depends on circRNA formation for translation. Specific vectors for expression of proteins from circRNAs have been developed [53]. The circRNA translational reporters often rely on heterologous flanking intronic sequences, provided for example by the highly expressed circZKSCAN1 gene. However, heterologous and authentic flanking introns can give

different amounts of circRNAs and circRNA-encoded protein expression [54]. The reporter gene assays can produce artefacts, such as trans-splicing [55], and expression of linear byproducts [56]. **These problems can be addressed by controls, such as comparison with mutated splice sites (GT->TT), introduction of in frame stop codons or splitting up the epitope tag in the backsplice site.**

General features of proteins made from circular RNAs

In their capacity to encode proteins, circular RNAs are distinct from linear RNAs as they can undergo rolling circle translation, where the ribosome moves around the circular RNA. Due to the backsplicing mechanism, circRNAs lack the first exon of mRNAs that cannot provide a 3' splice site.

Circular RNAs can increase proteome diversity through frameshifts during rolling circle translation.

The potential of circRNA rolling circle translation is illustrated by a 220 nt long circular RNA that represent the viroid-like satellite RNA of the rice yellow mottle virus. Viroids are single stranded circular RNAs that infect flowering plants and that potentially are also present in prokaryotes [58]. **The 220 nt long viroid-like satellite RNA can undergo three rounds of rolling circle translation where the reading frame shifts during each round of translation. The three frameshifts generate three distinct proteins of 16-, 18-, and 23 kDa from only 220 nt genetic information [59].**

The circular RNA translation allows the generation of novel proteins that contain parts of the full-length linear proteins. If the number of nucleotides of a circRNA cannot be divided by three (is not an integer of three) frameshifts will occur during translation, which generates proteins with a specific amino-terminus, carboxy terminus or both a specific amino and carboxy terminus. If the circular RNA lacks stop codons and the number of nucleotides can be divided by three, multimers of proteins can be generated using rolling circle translation. The number of rounds of translation can be from 1.5 to more than five and depends on the circRNA and cell type. In some cases, the circRNA encodes a completely new protein using a circRNA-specific reading frame [61,62] (Figure 2A).

Backsplicing frequently removes membrane-translocation signals.

A common feature of circRNA encoded proteins is that they change membrane association, which affects the intracellular localization. Proteins can be inserted into the membrane or enter the endoplasmic reticulum when they express a signal peptide at their amino-terminus. This 16-30 amino acid long hydrophobic sequence binds to the signal recognition particle and enters the endoplasmic reticulum through the signal recognition particle (SRP) receptor. The signal peptide is usually located in the first exon that lacks a 3' splice site and can thus not participate in backsplicing. Thus genes encoding proteins localized in the endoplasmic reticulum, Golgi or endosomes as well as membrane proteins can generate cytosolic variants using backsplicing (Figure 2B), which has been confirmed for CircCadherin and circINSIG1 [65].

The presence of non-coding exons in the 5' UTR are exceptions to this mechanism. For example, the first exon of presenilin 1 pre-mRNA is non-coding and the circPSEN1 RNA formed by backsplicing to exon 2 contains the start codon with the signal peptide. CircPSEN1 RNA is present in polysomes and thus likely translated.




Figure 2. Protein variants generated through backsplicing.A. Schematic structures of proteins made from circular RNAs, shown in Table 1. Sequences are in Supplemental Figure 1.B. CircRNAs encode proteins lacking a transmembrane domain. Most transmembrane domains are encoded by the first exon that lacks a 3' splice site and is not included in the circRNAs. Thus, the resulting circRNA encoded protein lacks the transmembrane domain and is likely cytosolic. C. Rolling circle translation. Proteins are made from a methionine usually, but not always, in the same reading frame as in the linear mRNA until a stop codon is encountered. If there is a change in reading frame between exon 1 and exon 2, circRNA-specific N and C-terminus is generated. Adenosine to inosine RNA editing can generate novel start codons by changing a AUA (Ile) into an AUI start codon. In the absence of a stop codon, rolling circle translation generates an indefinite ORF, where protein production stops after several rounds of translation via an unknown mechanism.

Currently known translated circular RNAs

Experimentally validated circRNA-encoded proteins are summarized in Table 2. Most of the circRNA encoded proteins play a role in cancer, which reflects the current research focus and possibly are due to hypoxia conditions in tumors that promote circRNA translation. The structures of the proteins are given in **Supplemental Table 1**, where circRNA-specific protein parts are indicated. Reflecting the backsplicing mechanism, the circRNA encoded proteins are smaller than mRNA encoded proteins, with an average size of 268 aa (human mean 456 aa, [66]). 36% (12/33) of the experimentally studied proteins show a high propensity (>0.8) for phase separation calculated by

MolPhase [67], indicating that they could form aggregates. The mean molecular recognition features (MoRF) for circRNA encoded proteins is 12.75%, compared to 1% to eukaryotic proteins, indicating that circRNA encoded proteins have a high likelihood to interaction with other proteins and adopt a structure upon binding (**Supplemental Table 2**). Thus, circRNA-encoded proteins likely have different biophysical characteristics than mRNA encoded proteins and could change cellular properties once translated.

Mechanisms of circular RNA translation

Cap dependent translation initiation of mRNAs

Cellular circRNAs were initially considered non-protein coding RNAs, because they lack a 5' 7-methyl guanosine cap or known ribosomal entry sites necessary for translational initiation. Thus, circRNA cannot be translated similar to the vast majority of mRNAs in a cap-dependent manner. The 40S ribosomal subunit binds to a ternary complex of eukaryotic initiation factors eIF2 bound to Met-tRNA(i) and GTP, which binds to the 40S ribosomal subunit with the help of eIF1, eIF1A, eIF3 and eIF5, generating the 43S ribosomal pre-initiation complex. This 43S complex binds to the mRNA cap via eIF4E, via the initiation factors eIF4E, and also contains eIF4G and A as well as PABPC2 (polyA binding protein C2). The 43S preinitiation complex then scans the mRNA for the AUG start codon. Thus, the translational initiation complex 'sees' a circular RNA structure, mediated by protein interactions between the 7-methyl guanosine cap (**7mG**) and the poly adenosine tail [69,70] (**Figure 3A**).

Cap independent translation initiation of mRNAs

Under cellular stress conditions, caused by hypoxia, nutrient starvation, oxidative or endoplasmic reticulum stress, mRNAs can be translated without a 7mG cap [70]. Cap-independent translation has been first discovered in viruses, where an internal ribosomal entry site (IRES) is present [71]. **The IRES forms tertiary RNA structures that interact with the 40S rRNA allowing to recruit the 43S pre-initiation complex (reviewed in [72]).** IRESes act through various mechanisms, including direct rRNA-IRES contacts and trans-acting factors mediated contacts. **After their discovery in viruses, IRESes have been identified in many cellular mRNAs** and cap-independent translation using IRES sequences is potentially used by up to 15% of human mRNAs [73], [74].

A second mechanism of cap independent translation is methylation of adenosine on the N6 position, called m6A. M6A modifications are one of the most common RNA modifications likely present in all classes of RNAs (reviewed in [75]). The m6A methylation is catalyzed by METTL3 (methyltransferase like 3), which needs cofactors for positioning which is provided by METTL14 for circRNAs. M6A modification are reversible and can be removed by fat mass and obesity associated protein (FTO) and AlkB homolog 5 (ALKBH5). M6A modifications are recognized by the YTH domain (yeast two hybrid, after YTH521-B, now YTHDC1, [76]). M6A modifications influence RNA stability, tertiary structure, subcellular localization, and pre-mRNA processing. M6A modification promotes circRNA formation, likely mediated by its nuclear reader YTHDC1 [77]. YTHDF1 promotes cap-dependent translation of m6A modified mRNAs by interacting with eIF3 [78], **which can make mRNA translation independent of the 7mG cap under cellular stress conditions (Figure 2B).**

Thus, numerous mRNAs undergo cap-independent translation that usually occurs under cellular stress conditions, such as hypoxia and is frequently observed in cancer [70].

Bacterial RNA lacks a 5' cap and translational initiation is mediated by mRNA-ribosome interaction. This explains why circular RNAs can also be translated in bacteria, which has been observed in the first translated circRNAs from archaea and has been suggested as a protein expression platform. In this approach circRNAs are generated as a group I intron and are translated by E. coli if the Shine-Dalgarno Sequence and the downstream sequence element surrounding the AUG start codon are present [80]. This mechanism could be physiologically important, as viroid-like circular RNAs were discovered in the microbiome of the human gut [81].

Given the widespread use of cap-independent translation in cellular mRNA, it is not surprising that circular RNAs can be translated as well, especially under stress conditions in cancer. Three major models have been proposed for circRNA translation [82]: internal ribosomal entry sites (IRES), m6A

methylation, adenosine to inosine RNA editing and 40S recruitment via eIF4A3 that is deposited on exon junctions.




Figure 3. Translation initiation mechanisms. Cap dependent translational initiation:

Schematic illustration of the cap-dependent translational initiation complex. Eukaryotic initiation factors are in green, RNA modification readers in blue. **B. Cap dependent translational initiation of m6A methylated mRNA:** M6A methylation promotes formation of the cap-dependent translational initiation complex by stabilizing the interaction of the 40S subunit through interaction of the m6A reader YTHDF1 with eIF3. **C. m6A-methylation dependent translation of circular RNAs:** The complex of methyltransferases 3 and 14 catalyzes m6A methylation of adenosines. M6A binds to the YTHDF3, which binds to eIF3G that recruits the 40S rRNA subunit. **D. RNA editing dependent translation of circular RNAs:** ADAR activity (ADAR1, ADAR2, adenosine deaminase acting on RNA) modifies adenosines to inosines that bind to an unknown reader, which binds to the 40S rRNA subunit, initiating translation at the AUG indicated (arrow). **E. Splicing dependent translation of circular RNAs:** eIF4A3 is part of the exon junction complex, which binds to the border of former exons spliced together (arrow). eIF4A3 interacts with eIF3G that initiates translation.

Internal ribosomal entry sites of circRNAs

The introduction of viral IRESes into circRNA strongly increased translation through eIF4G recruitment, leading to translation [43]. A systematic screen for ribosomal entry sites using GFP reporters identified 97 purine rich hexamer sequences in circRNAs that promote translation [83]. The identified hexamers partially overlap with m6A sites but given the presence of adenosines these sequences could also be substrates for A>I editing. The potential m6A sites are annotated in databases and computational analysis using known translated circRNAs identified short, A-U rich putative ribosomal entry sites [84]. As screen that looked at longer RNA regions, taking circRNA structure and complementarity to 18S rRNA into account identified over 17,000 possible circRNA IRES

sequences [85], possibly indicating that circRNA use several molecular mechanisms for translational initiation.

m6A methylation of circRNAs promotes their translation.

Using an siRNA screen, it was found that the m6A reader YTHDF3 is responsible for the translation of circRNAs, but YTHDF3 knock out did not affect mRNA translation. YTHDF3 binds directly to eIF4G2, leading to cap-independent circRNA translation [77,86]. At least 13% of circRNAs show m6A modification, indicating that m6A could contribute to the translation of numerous circRNAs. Analysis of pachytene spermatocytes showed that backsplicing occurred mostly at m6A enriched sites, resulting in the validated translation of 1,600 circular RNAs [51], **demonstrating a general role of m6A modification in circRNA translation.**

Splicing- promoted translation of circular RNAs through the exon junction complex.

During the splicing reaction, an exon junction protein complex is deposited on the nascent mRNA. The exon junction complex is necessary for RNA export into the cytosol and is composed of eIF4A3, MAGOH, Y12/RBM8A and CASC3 [87,88]. Every circRNA generated by backsplicing contains an exon junction and thus has possibly eIF4A3 bound. EIF4A3 likely plays a role in circRNA biogenesis as it promotes circRNA formation of some circRNAs [89-91]. eIF4A3 initiates translation by recruiting eIF3 through direct interaction with its subunit eIF3G. eIF3 recruits the small 40S ribosomal subunit that scans for a start codon, which initiating translation. This mechanism has been found for luciferase-reporter genes and translation of the circCTNNB1 (beta catenin) RNA [92], circINSIG1 and for the translation of succinate dehydrogenase assembly factor 2 (circSDHAF2) [93]. CircINSIG1 translation is likely promoted by hypoxia acting on eIF4A3. Notably, circSDHAF2 contains no known m6A-enhancers or m6A modifications. Its translation is further enhanced by the presence of introns, suggesting that translation of this circRNA mainly depends on the exon junction complex [93].

Inosine-dependent translational initiation

CircRNAs form intermolecular double stranded regions [54,57] making them substrates for ADAR enzymes (adenine deaminase acting on RNA) that recognize double stranded RNA structures and convert adenosines into inosines [94]. A screen of trans-acting factors found that ADAR1 and ADAR2 strongly increases translation of the circTau RNAs [54]. In humans, there are three different ADAR genes: ADAR1-ADAR3. ADAR1 is expressed in all tissues with an interferon-induced cytosolic (p150) and a constitutive nuclear (p110) isoform; ADAR2 is weakly expressed in brain and the catalytic inactive ADAR3 gene is highly expressed in brain. ADAR1-p150 has the strongest effect on circRNA translation [95], possibly due to its cytosolic localization. ADAR activity results in decoding of RNAs, as an inosine is read as a guanosine and thus an AUA changed into an AUI could serve as a start codon. This decoding was shown for circTau 12->10 RNA, generated by backsplicing of exon 12 to exon 10. This 288 nt long circRNA does contains an indefinite open reading frame, but lacks start or stop codon. ADAR activity changes an AUA to AUI, which initiates translation in reporter gene assays, showing that in principle ADAR activity can change the amino acid usage of circRNAs [54], **(Figure 2)**. RNAseq of reporter genes in the presence of co-transfected ADAR enzymes showed a widespread change of adenosines to inosines. In most positions less than 10% of a given adenosine site is changed. The editing profile depends on the flanking introns, suggesting that at least some of the editing occurs in the nucleus. The major substrates for ADAR enzymes in humans are RNAs derived from Alu-elements [16], suggesting that human circular RNAs surrounded by Alu elements might show differences in translation. The circTau reporter genes did not show a strong increase in translation when m6A-dependent circRNA translation was initiated. However, when both pathways were activated, an additive effect was seen [96].

The trans-acting factors connecting circRNA translation to their A>I editing are unknown. Several proteins, NOGO, p54nrb and vigilin/HDLBP were shown to predominantly bind to inosines and vigilin/HDLBP directly interacts with the 40S rRNA subunit [98], indicating that vigilin HDLBP might promote translational initiation of edited circRNAs, i.e. it could act as a reader for inosines.

Circular RNAs as inhibitors of mRNA translation

Several reports indicate that circular RNAs interact with ribosomes, which can inhibit translation. For example, circHIPK2 binds directly to the pre-ribosomal initiation factor RPL7, which inhibits myogenesis [99]. Similarly, circTRPS1 binds to several ribosomal proteins, which reduces translation [100]. Testing translation of specific mRNAs, it was found that circMALAT1 inhibits PAX5 mRNA translation [101], circSMAD2 sequesters eIF4A3 which inhibits translation of linear SMAD2 [102].

Outlook

circRNAs are translated under conditions that favor cap-independent translation, which in most cases studied is cellular stress seen in cancer or in neurodegeneration. Thus, most circRNA encoded proteins are associated with cancer which likely also reflects a research focus. In addition, circular RNAs translation becomes apparent when mRNAs are removed, as in stages during sperm cell development. There are at least three different translational mechanism for circRNAs: internal ribosomal entry sites, m6A modification, and RNA editing.

The number of known circRNA isoforms far exceeds the number of mRNA isoforms suggesting that protein encoded by circRNAs can provide special functions to an organism, especially the nervous system that shows the highest expression of circRNAs. Some circRNAs like LINC-PINT are derived from non-coding RNAs and could thus lead to proteins made from non-coding RNAs and potentially other uncapped RNAs such as DWORF [103].

CircRNAs are highly stable, allowing the accumulation of RNA modifications, which is the basis of at least two circRNA translational mechanisms. As more than 100 RNA modifications are known, it is possible that other RNA modifications could lead to circRNA translation and there is some evidence the N1-methyladenosine could contribute to circRNA translation [104].

The stability of circRNAs makes them attractive as vectors for protein delivery and circRNAs have been suggested as vaccine platforms [105]. The expression of some circRNA-encoded proteins is tumor-specific, making them targets for possible anti-tumor vaccines [106-108]. Finally, circRNAs could be therapeutic targets using siRNAs that target the unique backsplice junction [109,110].

Table 1. Resources and databases for circular RNAs. List of web-based resources useful to study circRNAs.

FL-circAS	Full-length circular RNA sequences, shows internal sequences and alternative splicing	[10]
circVis	Visualization of circRNA	[111]
circNET 2.0	Regulatory network in cancer	[112]
circMine	Disease related circRNAs	[113]
riboCirc	Translatable circRNA	[47]
transCirc	Translatable circRNA	[41]
Circ2Disease	circRNAs in human disease	[114]
CircInteractome	Database of circRNA interaction with miRNAs and proteins	[38]

Table 2. Validated proteins made from circular RNAs.Summary of validated proteins encoded by circRNAs. Alu-elements indicate the presence of Alu elements in introns directly flanking the first and last exon on the circRNA, L: left intron, R: right intron, B: both introns. For iORFs generated by rolling circle, the length of one round is indicated. RC: rolling circle. aa_nb: number of amino acids.

#	Name	aa_nb	validation	function	Summary function	circRNA length (nt)	Alu	Number of	References
1	LINC-PINT	87	Mass-spectrometry, antiserum	Suppresses glioblastoma cell proliferation	LINC-PINT Long Intergenic Non-Protein Coding RNA, (also p53 Induced Transcript) forms a circular RNA from exon 2, There is no protein translation from the LINC-PINT transcript, however, there is translation from the circular RNA. The 87 amino acid long protein binds to PAF1 (polymerase associated factor (PAF1) complex. The protein could arrest the PAF1 complex on promoters of oncogenes, leading to a suppression of cell proliferations in glioblastoma.	1084	no	1	[61]
2	circSHPRH	146	Mass-spectrometry, antiserum	Inhibits tumor cell proliferation	SHPRH (Histone Linker PHD RING Helicase [SNF: sucrose non fermenting]), forms a 440 nt long circRNA through backsplicing from exon 29 to 26. The 440 nt long circRNA is translated into circSHPRH-146aa. The protein could act by sequestering the ubiquitin E3 ligase DTL that then no longer acts and destabilizes the linear SHPRH protein. The full length SHPRH causes PCNA degradation, and thus circSHPRH-146aa indirectly stops proliferation of glioblastoma cells. circSHPRH-146 is downregulated in glioblastoma. The protein starts and stops within the same 4 nucleotides: TGATG it starts at ATG, and due to frameshift uses TGA as stop.	440	L	4	[115], [116]

3	circFBXW7	185	Mass-spectrometry, antiserum	represses glioma tumorigenesis	FBXW7 (F-Box And WD Repeat Domain Containing 7, E3) is part of an ubiquitin ligase complex acting as a E3 ligase. The circFBXW7 protein corresponds to the N-terminus and lacks the WXD40 domain necessary for substrate recognition. circFBXW7 competes with the linear FBXW7 for binding to the deubiquitinase USP28. Thus, an increase in amount of circFBXW7 frees linear FBXW7 protein for substrate degradation, which was shown for c-Myc. circFBXW7 interacts with catenin, influences Wnt signal, leading to cancer cell resistance	620	no	2	[117], [118]
4	circCDH1	254	Mass-spectrometry, antiserum	Activates EGF receptor	circCDH1 (Cadherin 1) is generated through backsplicing from exon 10 to 7 in the E-cadherin gene. Due to a frameshift after one round of translation a unique C-terminus is created. The circRNA was detected in 84% of glioma, but not in controls. The circCDH1 activated STAT3, PI3K-AKT and MAPK-ERK signaling in glioblastoma. In contrast to linear E-cadherin that is localized in the plasma membrane, circCDH1 is secreted out of cells and binds and activates EGFR using its circRNA-specific region. The circular RNA encoded protein contain cadherin domains but lacks a transmembrane domain and the signal peptide. The activation of EGFR promotes tumor formation and prevents the therapeutic effect of an anti EGFR-antibody (nimotuzumab).	733	B	4	[64]
5	circINSIG1	131	Mass-spectrometry, antiserum	Induces cholesterol biosynthesis and colorectal cancer	INSIG1 (Insulin Induced Gene 1) is an endoplasmic reticulum membrane domain protein with six transmembrane regions. Backsplicing from exon 4 to 3 generates circINSIG1 that has a specific C-terminus. circINSIG1 recruits a ubiquitination adaptor complex made from the proteins CUL5 and ASB6. This complex promotes ubiquitination and degradation of the linear INSIG1 protein, which promotes cholesterol biosynthesis and colorectal cancer proliferation and metastasis.	292	no	2	[65]
6	circNFIB	RC	Polysome	Inhibits breast tumor growth,	NFIB (Nuclear Factor I B) is a transcriptional activator. Backsplicing of exon 6 to 3 generates a 361 circular RNA that undergoes rolling circle translation. The circNFIB is downregulated in breast cancer. Its overexpression prevents cancer cell proliferation, whereas knock down has the opposite effect.	361	no	4	[119]

7	circZNF609	250	Polysome , reporter gene	Controls myoblast proliferat	ZNF609 (zinc finger protein 609) forms a circRNA through backsplicing of exon 2.	874	B	1	[120]
8	circYAP	220	Mass- spectrometr y,	binds to LATS1	circYAP is generated through backsplicing of exon 7 to 2 of YAP1.circYAP competes with linear YAP for binding to the kinase LATS1, causing loss of phosphorylation of linear YAP that translocated into the nucleus and turns on oncogenic transcription program. The translation occurs via METT3/14, YTHDF3 eIF4G2.	842	B	5	[29]
9	circFAM53B	219	Mass- spectro metry,	Inhibits tumor growth	circFAM53B (Family with Sequence Similarity 53 Member B) regulates the Wnt signaling pathway by regulating beta-catenin (CTNNB1) nuclear localization	659	no	1	[106]
10	circ Beta TRCP (HUGO name: BTRC)	343	Mass-spectrometry, antiserum	Protein mediates trastuzumab resistance by binding to NRF2	Beta-Transducin Repeat Containing E3 Ubiquitin (BTRC) generates circ Beta TRCP through backsplicing of exon 13 to exon 7. circ Beta TRCP contains WD40 repeats that bind to NRF2 and promotes trastuzumab resistance in breast cancer. In contrast to the linear proteins, circ Beta TRCP lacks an F box needed to bind to the ubiquitination complex SKP1-Cul1-Rbx1. Thus, circ Beta TRCP prevents NRF2 from being ubiquitinated, leading to an increase in NRF2, which promotes HER2-positive breast cancer.	913	B	7	[30]
11	circMET	404	polysomes, antiserum, mass-spectrometry	Promotes glioblastoma	MET (MET Proto-Oncogene, Receptor Tyrosine Kinase) generates circMET through backsplicing its exon 2, which is the first coding exon in the pre-mRNAs. The circRNA is translated after undergoing m6A modification, mediated by YTHDF2. The circMET protein contains the signal peptide and the protein is secreted and binds to the extracellular domain of the linear MET protein, which promotes dimerization without the physiological HGF (hepatocyte growth factor) ligand. circMET promotes glioblastoma tumorigenicity through MET activation.	1214	no	1	[121]

12	circCAPG	171	Mass-spectrometry	Promotes breast cancer by binding of serine/threonine kinase 38 (STK38) to SMAD-specific E3	CAPG (Capping Actin Protein, Gelsolin Like) binds to the barbed ends of F-actin filaments regulating the filament's length. Backsplicing of exon 8 to exon 6 generates circCAPG. The circCAPG levels are elevated in triple negative breast cancer and promote tumor growth. It sequesters serine threonine kinase 38, which ultimately prevents MEKK2 proteasomal degradation. The formation of the circRNA is repressed by the splicing factor SLU7, possibly acting on the flanking Alu elements.	376	B	3	[19]
13	circRSRC1	161	polysomes, mass-spectrometry	Regulates assembly of mitochondrial ribosomes. Loss of	RSRC1 (Arginine and Serine Rich Coiled-Coil 1), acts in alternative splicing. Backsplicing from exon 3 to 2 creates a circRSRC1, that is highly conserved between mouse and human. Knock out in mice reduced spermatogenesis. circ RSRC1 binds to C1qbp (Complement C1q Binding Protein), a multifunctional protein. Through interaction with C1qbp, circ RSRC1-161aa could influence mitochondrial ribosome assembly.	322	R	2	[122]
14	circTMEFF1	RC 3x	polysomes, reporter genes	Promotes muscle atrophy through binding to TDP-43	TMEFF1 (Transmembrane Protein with EGF Like And Two Follistatin Like Domains 1) in involved in receptor signaling. It forms a circular RNA by backsplicing of exon 7 to 5 that is upregulated in muscular atrophy. circTMEFF1 promotes atrophy in cell and mouse models, which can be antagonized by siRNAs.	339	R	3	[123]

16	circPPP1R12A	72	Mass-spectrometry from reporter constructs	Activates YAP, promotes metastasis	PPP1R12A (Protein Phosphatase 1 Regulatory Subunit 12A), also known as Myosin phosphatase target subunit 1, regulates myosin-actin interaction. Backsplicing of exon 25 to 24 generates circPPP1R12A. The encoded protein is in a different reading frame than the linear protein and has no orthologs in the protein database. The protein promotes metastasis by indirectly affecting the phosphorylation of YAP, which activates oncogenes.	1138	R	2	[62], [124]
17	circGSPT1	238	mass-spectrometry	Binds to vimentin tumor suppressor	GSPT1 (G1 To S Phase Transition 1) is acting in translational termination, also known as eukaryotic release factor 3A (eRF3A). Backsplicing from exon 11 to 4 generates circGSPT1that promotes autophagy and apoptosis in cancer cell models by binding to Vimentin/beclin/14-3-3. CircGSPT1is downregulated in gastric cancer, and act like a tumor suppressor.	826	L	6	[125]
18	circMAPK14	175	mass-spectroscopy	Binds to MKK6	MAPK14 (Mitogen-Activated Protein Kinase 14) is a serine/threonine kinase activated by environmental stress or cytokines. It generates circMAPK14 through backsplicing of exon 10 to 4. circMAPK14. is downregulated in colorectal colon cancer reduces proliferation. Both linear and circular MAPK14 bind to MAP2K6 (aka MKK6, Mitogen-Activated Protein Kinase Kinase 6) and circMAPK14 antagonizes the linear MAPK14 MAP2K6 interaction, leading to a change in a transcriptional program.	506	L	6	[126]
19	circPLCE1	411	mass spectrometry from a reporter gene	Influenced NFκB through ubiquitination	PLCE1 (Phospholipase C Epsilon 1) hydrolyzes phosphatidylinositol-4,5-bisphosphate generating inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Backsplicing of its exon 2 genererates circPLCE1 that is downregulated in colectoral carcinoma. CircPLCE1 promotes cancer cell proliferation and metastasis. By sequestering HSP90alpha in the HSP90alpha/RPS3 complex, leading to RPS3 ubiquitination and degradation. This pathway is disturbed in cancer cells due to the reduced circPLCE1 expression, which ultimately leads to NF kappa B activation in the nucleus and a tumor program.	1570	no	1	[127]

20	circCTNNB1	370	mass spectrometry from a reporter gene	promotes migration and proliferation of cancer cells.	CTNNB1 (Catenin Beta 1) is part of adherents junctions that regulate cell-cell interactions and forms circCTNNB1 by backsplicing of exon 7 to 2. circCTNNB1 is upregulated in liver cancer and non-small lung cell carcinoma tissue and competes with the full length CTNNB1 for phosphorylation by GSK3. As the phosphorylation leads to degradation of the protein, circ CTNNB1 ‘protects’ full length CTNNB1 from degradation, allowing the full-length protein to activate the Wnt/beta catenin pathway.	1068	no	5	[128], [129]
21	circARHGAP35	1289	Mass-spectrometry of reporter genes, polysomes.	Encoded protein promotes cancer cell progression	ARHGAP35 (Rho GTPase Activating Protein 35) is a cytosolic GTPase activating protein. It creates circARHGAP35 by backsplicing exon 2 to exon 3, The circRNA is upregulated in hepatocellular carcinoma and promotes proliferation and metastasis. In contrast to the cytosolic linear protein, the circular protein is nuclear and still contains FF domains, necessary for binding to TFII-I, which likely starts a cancerogenic expression program.	4014	L	2	[31]
22	circEGFR	RC	mass-spectrometry using reporter	Prevents receptor endocytosis	EGFR (Epidermal Growth Factor Receptor) is a transmembrane protein acting as protein kinase upon acidification. Backsplicing of exons15 to 14 creates circEGFR encode an infinite open reading frame (iORF). The circprotein remains associated with the cell membrane and prevents endocytosis and inactivation of the receptor. The circRNA is upregulated in glioblastoma and expression levels correlate with survival.	249	B	2	[60]
23	CircAPP	175	mass-spectrometry from reporter genes and brain tissue	circAPP was identified in sporadic AD	APP (Amyloid Beta Precursor Protein) is a cell surface receptor that is cleaved by secretases into a number of peptides, some of them form protein aggregates involved in Alzheimer’s disease. The gene creates a circular RNA by backsplicing exon 17 to 14.	524	B	4	[130]

24	circFNDC3B	218	mass spectrometry	Inhibits proliferation of cancer cells	FNDC3B (Fibronectin Type III Domain Containing 3B) is a single pass membrane protein present in the endoplasmic reticulum and the plasma membrane. It generates circFNDC3B through backsplicing from exon 6 to 5. circFNDC3B expression is downregulated in colorectal cancer cells. circ FNDC3B inhibits the proliferation of colorectal cancer cells, possibly by inhibiting the expression of SNAIL, a transcriptional regulator that inhibits FBP1 (Fructose-Bisphosphatase 1) expression.	526	L	2	[131]
25	circRTN4 (mouse)	RC	mass-spectrometry using	To be determined	Mouse Reticulon 4 (RTN4) generates a circRTN4 by backsplicing exon 3 to 2.	2457	B	2	[132]
26	circNlgn (mouse)	173	Antisera, mass-spectrometry	Promoter activation	Neurologin 1 is a neuronal cell surface protein. It generates circNlgn. through circularization of its first coding exon that includes the signal peptide. The encoded protein has 9 circRNA specific amino acids at its C-terminus that interact with Lamin B1, leading to the nuclear localization of the circRNA protein where it activates promoters of ING4 and C8orf44-SGK3 genes that impacts on cardiac fibroblast proliferation. Transgenic mice with circNlgn-173 have a heart phenotype	813	B	1	[133]
27	circAXIN1	295	Antisera and mass-spectrometry	Highly expressed and associated with lymph node metastasis in gastric cancer	AXIN1 (Axis Inhibition Protein 1) encodes a protein phosphatase. Circularization of exon 2 generates circAXIN1 that contains the start codon of the linear protein but has a unique C-terminus consisting of two amino acids TD. Circ AXIN1 binds competitively with APC, i.e., removes linear AXIN1. This releases beta catenin from a larger cytosolic complex. Beta catenin translocate into the nucleus and activates the wnt pathway, promoting gastric cell cancer growth.	959	R	1	[134]

28	circEIF6	224	Polysome, mass-spectrometry, antisera.	proliferation, and invasion of triple negative breast cancer	eIF6 (Eukaryotic Translation Initiation Factor 6) prevents the association of the 40S and 60S rRNA subunits during translation. It also known as Integrin beta 4 binding protein (ITGB4BP) and is part of hemidesmosomes that link the basal membrane to the cytoskeleton. Backsplicing from exon 7 to exon 3 generates circEIF6 promotes proliferation, and invasion of triple negative breast cancer cells. It binds to MYH9, which prevents MYH9 ubiquitination and degradation, leading to an activation of the Wnt/beta-catenin pathway	906	R	5	[135]
29	circHER2	103	polysome mass-spectrometry	promotes heterodimerization between	HER2 (Erb-B2 Receptor Tyrosine Kinase 2) is part of the epidermal growth factor receptor family. Through heterodimerization it enhances ligand binding and activation of other receptor kinases. Through backsplicing from exon 7 to 3, it creates circHER2, that is 100% identical to the linear one. CircHER2 expression correlates with poor survival in breast cancer.	750	no	5	[32]
30	circMAPT 12 to7	RC	Reporter genes	Tau aggregation	MAPT (microtubule associated protein tau) generates circTau RNA through backsplicing of exon 12 to 7. The encoded protein promotes aggregation of linear tau protein in reporter cells.	752	B	5	[54]
31	circMAPT 12 to 10	RC	Reporter genes and mass	Tau aggregation	MAPT (microtubule associated protein tau) generates circTau RNA through backsplicing of exon 10 to 7. This circTau RNA lacks a start codon, but is translated after undergoing A>I editing, likely creating a AUI start codon.	288	B	3	[54]
32	circMAN21-400	186	Reporter genes	circMAN2A1 expression	circMAN2A1 RNA expression correlates with Alzheimer’s disease progression. The encoded protein lacks a catalytic domain.	400	B	2	[95]
33	circSDHA2	146	Reporter genes	Tumor growth	SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2) is necessary for the flavination of a succinate dehydrogenase complex subunit A. SDHAF2 creates circSDHAF2 by backsplicing exon 4 to 3. Overexpression of circSDHAF2 promotes tumor growth.	334	B	2	[93]

34	circSLC8A1	605	Western blot using microsomes	Ca ⁺⁺ exchanger	<i>SLC8A1</i> (previously called NCX1) generates circSLC8A1 through backsplicing of exon 2. The protein lacks the hydrophobic domain of the linear protein but can still transport Ca ⁺⁺ across a membrane.	1832	no	1	[42]
----	------------	-----	-------------------------------	----------------------------	--	------	----	---	------

Acknowledgment: The work was supported by the National Science Foundation NSF MCB-2221921 and the NIH 1R21AG087332-01 to SS and GM130954 to DWR.

Abbreviations

7mG. 7-methylguanosine
 ADAR adenosine deaminase acting on RNA
 circRNA circular ribonucleic acid
 iORF. Infinite open reading frame
 IRES internal ribosomal entry sites
 M6A N6-methyladenosine
 MoRF mean molecular recognition features
 RNA ribonucleic acid
 RNase R ribonuclease R
 rRNA ribosomal RNA
 sORF short open reading frame
 SRP signal recognition particle

References

1. J.M. Nigro, K.R. Cho, E.R. Fearon, S.E. Kern, J.M. Ruppert, J.D. Oliner, K.W. Kinzler, B. Vogelstein, Scrambled exons, *Cell* 64 (1991) 607-613.
2. C. Cocquerelle, B. Mascrez, D. Hetuin, B. Bailleul, Mis-splicing yields circular RNA molecules, *FASEB J* 7 (1993) 155-160.
3. B. Capel, A. Swain, S. Nicolis, A. Hacker, M. Walter, P. Koopman, P. Goodfellow, R. Lovell-Badge, Circular transcripts of the testis-determining gene *Sry* in adult mouse testis, *Cell* 73 (1993) 1019-1030.
4. J. Kjems, R.A. Garrett, Novel splicing mechanism for the ribosomal RNA intron in the archaeobacterium *Desulfurococcus mobilis*, *Cell* 54 (1988) 693-703. 10.1016/s0092-8674(88)80014-x.
5. J. Salzman, C. Gawad, P.L. Wang, N. Lacayo, P.O. Brown, Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types, *PLoS One* 7 (2012) e30733. 10.1371/journal.pone.0030733.
6. W.R. Jeck, J.A. Sorrentino, K. Wang, M.K. Slevin, C.E. Burd, J. Liu, W.F. Marzluff, N.E. Sharpless, Circular RNAs are abundant, conserved, and associated with ALU repeats, *Rna* 19 (2013) 141-157. 10.1261/rna.035667.112.
7. R. Xin, Y. Gao, Y. Gao, R. Wang, K.E. Kadash-Edmondson, B. Liu, Y. Wang, L. Lin, Y. Xing, isoCirc catalogs full-length circular RNA isoforms in human transcriptomes, *Nat Commun* 12 (2021) 266. 10.1038/s41467-020-20459-8.
8. L. Hou, J. Zhang, F. Zhao, Full-length circular RNA profiling by nanopore sequencing with CIRI-long, *Nat Protoc* 18 (2023) 1795-1813. 10.1038/s41596-023-00815-w.
9. J. Zhang, L. Hou, Z. Zuo, P. Ji, X. Zhang, Y. Xue, F. Zhao, Comprehensive profiling of circular RNAs with nanopore sequencing and CIRI-long, *Nat Biotechnol* 39 (2021) 836-845. 10.1038/s41587-021-00842-6.
10. T.W. Chiang, S.E. Jhong, Y.C. Chen, C.Y. Chen, W.S. Wu, T.J. Chuang, FL-circAS: an integrative resource and analysis for full-length sequences and alternative splicing of circular RNAs with nanopore sequencing, *Nucleic Acids Res* 52 (2024) D115-D123. 10.1093/nar/gkad829.
11. M. Pertea, A. Shumate, G. Pertea, A. Varabyou, F.P. Breitwieser, Y.C. Chang, A.K. Madugundu, A. Pandey, S.L. Salzberg, CHES: a new human gene catalog curated from thousands of large-scale RNA sequencing experiments reveals extensive transcriptional noise, *Genome Biol* 19 (2018) 208. 10.1186/s13059-018-1590-2.
12. J.R. Welden, S. Stamm, Pre-mRNA structures forming circular RNAs, *Biochim Biophys Acta Gene Regul Mech* 1862 (2019) 194410. 10.1016/j.bbagr.2019.194410.

13. P. Deininger, Alu elements: know the SINEs, *Genome Biol* 12 (2011) 236. 10.1186/gb-2011-12-12-236.
14. L. Liang, C. Cao, L. Ji, Z. Cai, D. Wang, R. Ye, J. Chen, X. Yu, J. Zhou, Z. Bai, R. Wang, X. Yang, P. Zhu, Y. Xue, Complementary Alu sequences mediate enhancer-promoter selectivity, *Nature* 619 (2023) 868-875. 10.1038/s41586-023-06323-x.
15. E. Ullu, C. Tschudi, Alu sequences are processed 7SL RNA genes, *Nature* 312 (1984) 171-172. 10.1038/312171a0.
16. L. Bazak, A. Haviv, M. Barak, J. Jacob-Hirsch, P. Deng, R. Zhang, F.J. Isaacs, G. Rechavi, J.B. Li, E. Eisenberg, E.Y. Levanon, A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes, *Genome Res* 24 (2014) 365-376. 10.1101/gr.164749.113.
17. E.Y. Levanon, E. Eisenberg, R. Yelin, S. Nemzer, M. Hallegger, R. Shemesh, Z.Y. Fligelman, A. Shoshan, S.R. Pollock, D. Sztybel, M. Olshansky, G. Rechavi, M.F. Jantsch, Systematic identification of abundant A-to-I editing sites in the human transcriptome, *Nat Biotechnol* 22 (2004) 1001-1005. 10.1038/nbt996.
18. Y. Neeman, E.Y. Levanon, M.F. Jantsch, E. Eisenberg, RNA editing level in the mouse is determined by the genomic repeat repertoire, *RNA* 12 (2006) 1802-1809. 10.1261/rna.165106.
19. R. Song, P. Guo, X. Ren, L. Zhou, P. Li, N.A. Rahman, S. Wolczynski, X. Li, Y. Zhang, M. Liu, J. Liu, X. Li, A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer, *Mol Cancer* 22 (2023) 104. 10.1186/s12943-023-01806-x.
20. S.J. Conn, K.A. Pillman, J. Toubia, V.M. Conn, M. Salmanidis, C.A. Phillips, S. Roslan, A.W. Schreiber, P.A. Gregory, G.J. Goodall, The RNA binding protein quaking regulates formation of circRNAs, *Cell* 160 (2015) 1125-1134. 10.1016/j.cell.2015.02.014.
21. M.A. Khan, Y.J. Reckman, S. Aufiero, M.M. van den Hoogenhof, I. van der Made, A. Beqqali, D.R. Koolbergen, T.B. Rasmussen, J. van der Velden, E.E. Creemers, Y.M. Pinto, RBM20 Regulates Circular RNA Production From the Titin Gene, *Circ Res* 119 (2016) 996-1003. 10.1161/CIRCRESAHA.116.309568.
22. T. Fei, Y. Chen, T. Xiao, W. Li, L. Cato, P. Zhang, M.B. Cotter, M. Bowden, R.T. Lis, S.G. Zhao, Q. Wu, F.Y. Feng, M. Loda, H.H. He, X.S. Liu, M. Brown, Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing, *Proc Natl Acad Sci U S A* 114 (2017) E5207-E5215. 10.1073/pnas.1617467114.
23. R. Ashwal-Fluss, M. Meyer, N.R. Pamudurti, A. Ivanov, O. Bartok, M. Hanan, N. Evantal, S. Memczak, N. Rajewsky, S. Kadener, circRNA biogenesis competes with pre-mRNA splicing, *Mol Cell* 56 (2014) 55-66. 10.1016/j.molcel.2014.08.019.
24. A. Huang, H. Zheng, Z. Wu, M. Chen, Y. Huang, Circular RNA-protein interactions: functions, mechanisms, and identification, *Theranostics* 10 (2020) 3503-3517. 10.7150/thno.42174.
25. L.H. Ngo, A.G. Bert, B.K. Dredge, T. Williams, V. Murphy, W. Li, W.B. Hamilton, K.T. Carey, J. Toubia, K.A. Pillman, D. Liu, J. Desogus, J.A. Chao, A.J. Deans, G.J. Goodall, V.O. Wickramasinghe, Nuclear export of circular RNA, *Nature* 627 (2024) 212-220. 10.1038/s41586-024-07060-5.
26. K. Strasser, S. Masuda, P. Mason, J. Pfannstiel, M. Oppizzi, S. Rodriguez-Navarro, A.G. Rondon, A. Aguilera, K. Struhl, R. Reed, E. Hurt, TREX is a conserved complex coupling transcription with messenger RNA export, *Nature* 417 (2002) 304-308. 10.1038/nature746.
27. T. Puhringer, U. Hohmann, L. Fin, B. Pacheco-Fiallos, U. Schellhaas, J. Brennecke, C. Plaschka, Structure of the human core transcription-export complex reveals a hub for multivalent interactions, *Elife* 9 (2020). 10.7554/eLife.61503.
28. W. Ding, L. Ding, Y. Lu, W. Sun, Y. Wang, J. Wang, Y. Gao, M. Li, Circular RNA-circLRP6 protects cardiomyocyte from hypoxia-induced apoptosis by facilitating hnRNPM-mediated expression of FGF-9, *FEBS J* 291 (2024) 1246-1263. 10.1111/febs.17038.
29. K. Zeng, J. Peng, Y. Xing, L. Zhang, P. Zeng, W. Li, W. Zhang, Z. Pan, C. Zhou, J. Lin, A positive feedback circuit driven by m(6)A-modified circular RNA facilitates colorectal cancer liver metastasis, *Mol Cancer* 22 (2023) 202. 10.1186/s12943-023-01848-1.
30. S. Wang, Y. Wang, Q. Li, X. Li, X. Feng, K. Zeng, The novel beta-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer, *Redox Biol* 67 (2023) 102896. 10.1016/j.redox.2023.102896.

31. Y. Li, B. Chen, J. Zhao, Q. Li, S. Chen, T. Guo, Y. Li, H. Lai, Z. Chen, Z. Meng, W. Guo, X. He, S. Huang, HNRNPL Circularizes ARHGAP35 to Produce an Oncogenic Protein, *Adv Sci (Weinh)* 8 (2021) 2001701. 10.1002/advs.202001701.
32. J. Li, M. Ma, X. Yang, M. Zhang, J. Luo, H. Zhou, N. Huang, F. Xiao, B. Lai, W. Lv, N. Zhang, Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab, *Mol Cancer* 19 (2020) 142. 10.1186/s12943-020-01259-6.
33. V.A. Herzog, B. Reichholf, T. Neumann, P. Rescheneder, P. Bhat, T.R. Burkard, W. Wlotzka, A. von Haeseler, J. Zuber, S.L. Ameres, Thiol-linked alkylation of RNA to assess expression dynamics, *Nat Methods* (2017). 10.1038/nmeth.4435.
34. T.B. Hansen, T.I. Jensen, B.H. Clausen, J.B. Bramsen, B. Finsen, C.K. Damgaard, J. Kjems, Natural RNA circles function as efficient microRNA sponges, *Nature* 495 (2013) 384-388. 10.1038/nature11993.
35. M.T. Jarlstad Olesen, S.K. L., Circular RNAs as microRNA sponges: evidence and controversies, *Essays Biochem* 65 (2021) 685-696. 10.1042/EBC20200060.
36. A.C. Panda, Circular RNAs Act as miRNA Sponges, *Adv Exp Med Biol* 1087 (2018) 67-79. 10.1007/978-981-13-1426-1_6.
37. V.M. Conn, V. Hugouvieux, A. Nayak, S.A. Conos, G. Capovilla, G. Cildir, A. Jourdain, V. Tergaonkar, M. Schmid, C. Zubieta, S.J. Conn, A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation, *Nat Plants* 3 (2017) 17053. 10.1038/nplants.2017.53.
38. D.B. Dudekula, A.C. Panda, I. Grammatikakis, S. De, K. Abdelmohsen, M. Gorospe, CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs, *RNA Biol* 13 (2016) 34-42. 10.1080/15476286.2015.1128065.
39. A. Das, T. Sinha, S. Shyamal, A.C. Panda, Emerging Role of Circular RNA-Protein Interactions, *Noncoding RNA* 7 (2021). 10.3390/ncrna7030048.
40. F. Crudele, N. Bianchi, A. Terrazzan, P. Ancona, A. Frassoldati, P. Gasparini, A.P. D'Adamo, D. Papaioannou, R. Garzon, A. Wojcicka, P. Gaj, K. Jazdzewski, J. Palatini, S. Volinia, Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways, *Biology (Basel)* 12 (2023). 10.3390/biology12040493.
41. W. Huang, Y. Ling, S. Zhang, Q. Xia, R. Cao, X. Fan, Z. Fang, Z. Wang, G. Zhang, TransCirc: an interactive database for translatable circular RNAs based on multi-omics evidence, *Nucleic Acids Res* 49 (2021) D236-D242. 10.1093/nar/gkaa823.
42. X.F. Li, J. Lytton, A circularized sodium-calcium exchanger exon 2 transcript, *J Biol Chem* 274 (1999) 8153-8160.
43. C.Y. Chen, P. Sarnow, Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs, *Science* 268 (1995) 415-417.
44. N. Abe, K. Matsumoto, M. Nishihara, Y. Nakano, A. Shibata, H. Maruyama, S. Shuto, A. Matsuda, M. Yoshida, Y. Ito, H. Abe, Rolling Circle Translation of Circular RNA in Living Human Cells, *Sci Rep* 5 (2015) 16435. 10.1038/srep16435.
45. K. Nakamoto, N. Abe, G. Tsuji, Y. Kimura, F. Tomoike, Y. Shimizu, H. Abe, Chemically synthesized circular RNAs with phosphoramidate linkages enable rolling circle translation, *Chem Commun (Camb)* 56 (2020) 6217-6220. 10.1039/d0cc02140g.
46. L.V. Stagsted, K.M. Nielsen, I. Dugaard, T.B. Hansen, Noncoding AUG circRNAs constitute an abundant and conserved subclass of circles, *Life Sci Alliance* 2 (2019). 10.26508/lsa.201900398.
47. H. Li, M. Xie, Y. Wang, L. Yang, Z. Xie, H. Wang, riboCIRC: a comprehensive database of translatable circRNAs, *Genome Biol* 22 (2021) 79. 10.1186/s13059-021-02300-7.
48. A. Das, T. Sinha, S.S. Mishra, D. Das, A.C. Panda, Identification of potential proteins translated from circular RNA splice variants, *Eur J Cell Biol* 102 (2023) 151286. 10.1016/j.ejcb.2023.151286.
49. N.R. Pamudurti, O. Bartok, M. Jens, R. Ashwal-Fluss, C. Stottmeister, L. Ruhe, M. Hanan, E. Wyler, D. Perez-Hernandez, E. Ramberger, S. Shenzenis, M. Samson, G. Dittmar, M. Landthaler, M. Chekulaeva, N. Rajewsky, S. Kadener, Translation of CircRNAs, *Mol Cell* 66 (2017) 9-21 e27. 10.1016/j.molcel.2017.02.021.
50. B.P. Nicolet, S.B.G. Jansen, E. Heideveld, W.H. Ouwehand, E. van den Akker, M. von Lindern, M.C. Wolkers, Circular RNAs exhibit limited evidence for translation, or translation regulation

- of the mRNA counterpart in terminal hematopoiesis, *RNA* 28 (2022) 194-209. 10.1261/rna.078754.121.
51. C. Tang, Y. Xie, T. Yu, N. Liu, Z. Wang, R.J. Woolsey, Y. Tang, X. Zhang, W. Qin, Y. Zhang, G. Song, W. Zheng, J. Wang, W. Chen, X. Wei, Z. Xie, R. Klukovich, H. Zheng, D.R. Quilici, W. Yan, m(6)A-dependent biogenesis of circular RNAs in male germ cells, *Cell Res* 30 (2020) 211-228. 10.1038/s41422-020-0279-8.
 52. S. van Heesch, F. Witte, V. Schneider-Lunitz, J.F. Schulz, E. Adami, A.B. Faber, M. Kirchner, H. Maatz, S. Blachut, C.L. Sandmann, M. Kanda, C.L. Worth, S. Schafer, L. Calviello, R. Merriott, G. Patone, O. Hummel, E. Wyler, B. Obermayer, M.B. Mucke, E.L. Lindberg, F. Trnka, S. Memczak, M. Schilling, L.E. Felkin, P.J.R. Barton, N.M. Quaipe, K. Vanezis, S. Diecke, M. Mukai, N. Mah, S.J. Oh, A. Kurtz, C. Schramm, D. Schwinge, M. Sebode, M. Harakalova, F.W. Asselbergs, A. Vink, R.A. de Weger, S. Viswanathan, A.A. Widjaja, A. Gartner-Rommel, H. Milting, C. Dos Remedios, C. Knosalla, P. Mertins, M. Landthaler, M. Vingron, W.A. Linke, J.G. Seidman, C.E. Seidman, N. Rajewsky, U. Ohler, S.A. Cook, N. Hubner, The Translational Landscape of the Human Heart, *Cell* 178 (2019) 242-260 e229. 10.1016/j.cell.2019.05.010.
 53. R. Chen, S.K. Wang, J.A. Belk, L. Amaya, Z. Li, A. Cardenas, B.T. Abe, C.K. Chen, P.A. Wender, H.Y. Chang, Engineering circular RNA for enhanced protein production, *Nat Biotechnol* 41 (2023) 262-272. 10.1038/s41587-022-01393-0.
 54. J.R. Welden, G. Margvelani, K.A. Arizaca Maquera, B. Gudlavalleti, S.C. Miranda Sardón, A. Campos, N. Robil, D.C. Lee, A. Gonzalo Hernandez, W. Wang, J. Di, P. de la Grange, P.T. Nelson, S. Stamm, RNA editing of microtubule associated protein tau circular RNAs promotes their translation and tau tangle formation, *Nucleic Acids Res* 50 (2022) 12979-12996.
 55. H. Ho-Xuan, P. Glazar, C. Latini, K. Heizler, J. Haase, R. Hett, M. Anders, F. Weichmann, A. Bruckmann, D. Van den Berg, S. Huttelmaier, N. Rajewsky, C. Hackl, G. Meister, Comprehensive analysis of translation from overexpressed circular RNAs reveals pervasive translation from linear transcripts, *Nucleic Acids Res* 48 (2020) 10368-10382. 10.1093/nar/gkaa704.
 56. Y. Jiang, X. Chen, W. Zhang, Overexpression-based detection of translatable circular RNAs is vulnerable to coexistent linear RNA byproducts, *Biochem Biophys Res Commun* 558 (2021) 189-195. 10.1016/j.bbrc.2021.04.044.
 57. H.L. Sanger, G. Klotz, D. Riesner, H.J. Gross, A.K. Kleinschmidt, Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures, *Proc Natl Acad Sci U S A* 73 (1976) 3852-3856.
 58. B.D. Lee, U. Neri, S. Roux, Y.I. Wolf, A.P. Camargo, M. Krupovic, R.N.A.V.D. Consortium, P. Simmonds, N. Kyrpides, U. Gophna, V.V. Dolja, E.V. Koonin, Mining metatranscriptomes reveals a vast world of viroid-like circular RNAs, *Cell* 186 (2023) 646-661 e644. 10.1016/j.cell.2022.12.039.
 59. M.G. AbouHaidar, S. Venkataraman, A. Golshani, B. Liu, T. Ahmad, Novel coding, translation, and gene expression of a replicating covalently closed circular RNA of 220 nt, *Proc Natl Acad Sci U S A* 111 (2014) 14542-14547. 10.1073/pnas.1402814111.
 60. Y. Liu, Z. Li, M. Zhang, H. Zhou, X. Wu, J. Zhong, F. Xiao, N. Huang, X. Yang, R. Zeng, L. Yang, Z. Xia, N. Zhang, Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity, *Neuro Oncol* 23 (2021) 743-756. 10.1093/neuonc/noaa279.
 61. M. Zhang, K. Zhao, X. Xu, Y. Yang, S. Yan, P. Wei, H. Liu, J. Xu, F. Xiao, H. Zhou, X. Yang, N. Huang, J. Liu, K. He, K. Xie, G. Zhang, S. Huang, N. Zhang, A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma, *Nat Commun* 9 (2018) 4475. 10.1038/s41467-018-06862-2.
 62. X. Zheng, L. Chen, Y. Zhou, Q. Wang, Z. Zheng, B. Xu, C. Wu, Q. Zhou, W. Hu, C. Wu, J. Jiang, A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling, *Mol Cancer* 18 (2019) 47. 10.1186/s12943-019-1010-6.
 63. R. Sawada, S. Mitaku, How are exons encoding transmembrane sequences distributed in the exon-intron structure of genes?, *Genes Cells* 16 (2011) 115-121. 10.1111/j.1365-2443.2010.01468.x.
 64. X. Gao, X. Xia, F. Li, M. Zhang, H. Zhou, X. Wu, J. Zhong, Z. Zhao, K. Zhao, D. Liu, F. Xiao, Q. Xu, T. Jiang, B. Li, S.Y. Cheng, N. Zhang, Circular RNA-encoded oncogenic E-cadherin variant

- promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling, *Nat Cell Biol* 23 (2021) 278-291. 10.1038/s41556-021-00639-4.
65. L. Xiong, H.S. Liu, C. Zhou, X. Yang, L. Huang, H.Q. Jie, Z.W. Zeng, X.B. Zheng, W.X. Li, Z.Z. Liu, L. Kang, Z.X. Liang, A novel protein encoded by circINSIG1 reprograms cholesterol metabolism by promoting the ubiquitin-dependent degradation of INSIG1 in colorectal cancer, *Mol Cancer* 22 (2023) 72. 10.1186/s12943-023-01773-3.
 66. A. Tiessen, P. Perez-Rodriguez, L.J. Delaye-Arredondo, Mathematical modeling and comparison of protein size distribution in different plant, animal, fungal and microbial species reveals a negative correlation between protein size and protein number, thus providing insight into the evolution of proteomes, *BMC Res Notes* 5 (2012) 85. 10.1186/1756-0500-5-85.
 67. Q. Liang, N. Peng, Y. Xie, N. Kumar, W. Gao, Y. Miao, MolPhase, an advanced prediction algorithm for protein phase separation, *EMBO J* 43 (2024) 1898-1918. 10.1038/s44318-024-00090-9.
 68. J. Yan, A.K. Dunker, V.N. Uversky, L. Kurgan, Molecular recognition features (MoRFs) in three domains of life, *Mol Biosyst* 12 (2016) 697-710. 10.1039/c5mb00640f.
 69. H.J. Kim, Cell Fate Control by Translation: mRNA Translation Initiation as a Therapeutic Target for Cancer Development and Stem Cell Fate Control, *Biomolecules* 9 (2019). 10.3390/biom9110665.
 70. R. Lacerda, J. Menezes, L. Romao, More than just scanning: the importance of cap-independent mRNA translation initiation for cellular stress response and cancer, *Cell Mol Life Sci* 74 (2017) 1659-1680. 10.1007/s00018-016-2428-2.
 71. J. Pelletier, N. Sonenberg, Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA, *Nature* 334 (1988) 320-325. 10.1038/334320a0.
 72. C.U. Hellen, P. Sarnow, Internal ribosome entry sites in eukaryotic mRNA molecules, *Genes Dev* 15 (2001) 1593-1612. 10.1101/gad.891101.
 73. K.A. Spriggs, M. Stoneley, M. Bushell, A.E. Willis, Re-programming of translation following cell stress allows IRES-mediated translation to predominate, *Biol Cell* 100 (2008) 27-38. 10.1042/BC20070098.
 74. S. Weingarten-Gabbay, S. Elias-Kirma, R. Nir, A.A. Gritsenko, N. Stern-Ginossar, Z. Yakhini, A. Weinberger, E. Segal, Comparative genetics. Systematic discovery of cap-independent translation sequences in human and viral genomes, *Science* 351 (2016). 10.1126/science.aad4939.
 75. X. Wang, R. Ma, X. Zhang, L. Cui, Y. Ding, W. Shi, C. Guo, Y. Shi, Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions, *Mol Cancer* 20 (2021) 121. 10.1186/s12943-021-01415-6.
 76. P. Stoilov, I. Rafalska, S. Stamm, YTH: a new domain in nuclear proteins, *Trends Biochem. Sci.* 27 (2002) 495-496.
 77. G. Di Timoteo, D. Dattilo, A. Centron-Broco, A. Colantoni, M. Guarnacci, F. Rossi, D. Incarnato, S. Oliviero, A. Fatica, M. Morlando, I. Bozzoni, Modulation of circRNA Metabolism by m(6)A Modification, *Cell Rep* 31 (2020) 107641. 10.1016/j.celrep.2020.107641.
 78. X. Wang, B.S. Zhao, I.A. Roundtree, Z. Lu, D. Han, H. Ma, X. Weng, K. Chen, H. Shi, C. He, N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency, *Cell* 161 (2015) 1388-1399. 10.1016/j.cell.2015.05.014.
 79. K.D. Meyer, D.P. Patil, J. Zhou, A. Zinoviev, M.A. Skabkin, O. Elemento, T.V. Pestova, S.B. Qian, S.R. Jaffrey, 5' UTR m(6)A Promotes Cap-Independent Translation, *Cell* 163 (2015) 999-1010. 10.1016/j.cell.2015.10.012.
 80. R. Perriman, M. Ares, Jr., Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo, *RNA* 4 (1998) 1047-1054. 10.1017/s135583829898061x.
 81. I.N. Zheludev, R.C. Edgar, M.J. Lopez-Galiano, M. de la Pena, A. Babaian, A.S. Bhatt, A.Z. Fire, Viroid-like colonists of human microbiomes, *bioRxiv* (2024). 10.1101/2024.01.20.576352.
 82. H.J. Hwang, Y.K. Kim, Molecular mechanisms of circular RNA translation, *Exp Mol Med* (2024). 10.1038/s12276-024-01220-3.
 83. X. Fan, Y. Yang, C. Chen, Z. Wang, Pervasive translation of circular RNAs driven by short IRES-like elements, *Nat Commun* 13 (2022) 3751. 10.1038/s41467-022-31327-y.

84. Y. Zhou, J. Wu, S. Yao, Y. Xu, W. Zhao, Y. Tong, Z. Zhou, DeepCIP: A multimodal deep learning method for the prediction of internal ribosome entry sites of circRNAs, *Comput Biol Med* 164 (2023) 107288. 10.1016/j.compbiomed.2023.107288.
85. C.K. Chen, R. Cheng, J. Demeter, J. Chen, S. Weingarten-Gabbay, L. Jiang, M.P. Snyder, J.S. Weissman, E. Segal, P.K. Jackson, H.Y. Chang, Structured elements drive extensive circular RNA translation, *Mol Cell* 81 (2021) 4300-4318 e4313. 10.1016/j.molcel.2021.07.042.
86. Y. Yang, X. Fan, M. Mao, X. Song, P. Wu, Y. Zhang, Y. Jin, Y. Yang, L.L. Chen, Y. Wang, C.C. Wong, X. Xiao, Z. Wang, Extensive translation of circular RNAs driven by N(6)-methyladenosine, *Cell Res* 27 (2017) 626-641. 10.1038/cr.2017.31.
87. A. Nott, H. Le Hir, M.J. Moore, Splicing enhances translation in mammalian cells: an additional function of the exon junction complex, *Genes Dev* 18 (2004) 210-222. 10.1101/gad.1163204.
88. H.C. Lee, J. Choe, S.G. Chi, Y.K. Kim, Exon junction complex enhances translation of spliced mRNAs at multiple steps, *Biochem Biophys Res Commun* 384 (2009) 334-340. 10.1016/j.bbrc.2009.04.123.
89. Y. Zhang, W. Qi, Y. Wu, EIF4A3-induced circular RNA SCAP facilitates tumorigenesis and progression of non-small-cell lung cancer via miR-7/SMAD2 signaling, *Environ Sci Pollut Res Int* 30 (2023) 65237-65249. 10.1007/s11356-023-26307-8.
90. X. Li, C. Wang, G. Chen, W. Zou, Y. Deng, F. Zhou, EIF4A3-induced circCCNB1 (hsa_circ_0001495) promotes glioma progression by elevating CCND1 through interacting miR-516b-5p and HuR, *Metab Brain Dis* 37 (2022) 819-833. 10.1007/s11011-021-00899-x.
91. Z.H. Feng, L. Zheng, T. Yao, S.Y. Tao, X.A. Wei, Z.Y. Zheng, B.J. Zheng, X.Y. Zhang, B. Huang, J.H. Liu, Y.L. Chen, Z. Shan, P.T. Yuan, C.G. Wang, J. Chen, S.Y. Shen, F.D. Zhao, EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression, *Cell Death Dis* 12 (2021) 1025. 10.1038/s41419-021-04339-7.
92. J. Chang, M.K. Shin, J. Park, H.J. Hwang, N. Locker, J. Ahn, D. Kim, D. Baek, Y. Park, Y. Lee, S.H. Boo, H.I. Kim, Y.K. Kim, An interaction between eIF4A3 and eIF3g drives the internal initiation of translation, *Nucleic Acids Res* 51 (2023) 10950-10969. 10.1093/nar/gkad763.
93. H.H. Lin, C.Y. Chang, Y.R. Huang, C.H. Shen, Y.C. Wu, K.L. Chang, Y.C. Lee, Y.C. Lin, W.C. Ting, H.J. Chien, Y.F. Zheng, C.C. Lai, K.Y. Hsiao, Exon Junction Complex Mediates the Cap-Independent Translation of Circular RNA, *Mol Cancer Res* 21 (2023) 1220-1233. 10.1158/1541-7786.MCR-22-0877.
94. C.E. Samuel, Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses, *J Biol Chem* 294 (2019) 1710-1720. 10.1074/jbc.TM118.004166.
95. K.A. Arizaca Maquera, J.R. Welden, G. Margvelani, S.C. Miranda Sardón, S. Hart, N. Robil, A.G. Hernandez, P. de la Grange, P.T. Nelson, S. Stamm, Alzheimer's disease pathogenetic progression is associated with changes in regulated retained introns and editing of circular RNAs, *Frontiers in Molecular Neuroscience* 16 (2023). 10.3389/fnmol.2023.1141079.
96. G. Margvelani, J.R. Welden, A.A. Maquera, J.E. Van Eyk, C. Murray, S.C. Miranda Sardon, S. Stamm, Influence of FTDP-17 mutants on circular tau RNAs, *Biochim Biophys Acta Mol Basis Dis* 1870 (2024) 167036. 10.1016/j.bbadis.2024.167036.
97. Q. Wang, Z. Zhang, K. Blackwell, G.G. Carmichael, Vigilins bind to promiscuously A-to-I-edited RNAs and are involved in the formation of heterochromatin, *Curr Biol* 15 (2005) 384-391. 10.1016/j.cub.2005.01.046.
98. U. Zinnall, M. Milek, I. Minia, C.H. Vieira-Vieira, S. Muller, G. Mastrobuoni, O.G. Hazapis, S. Del Giudice, D. Schwefel, N. Bley, F. Voigt, J.A. Chao, S. Kempa, S. Huttelmaier, M. Selbach, M. Landthaler, HDLBP binds ER-targeted mRNAs by multivalent interactions to promote protein synthesis of transmembrane and secreted proteins, *Nat Commun* 13 (2022) 2727. 10.1038/s41467-022-30322-7.
99. J. Yan, Y. Yang, X. Fan, Y. Tang, Z. Tang, Sp1-Mediated circRNA circHpk2 Regulates Myogenesis by Targeting Ribosomal Protein Rpl7, *Genes (Basel)* 12 (2021). 10.3390/genes12050696.
100. R. Zhao, P. Chen, C. Qu, J. Liang, Y. Cheng, Z. Sun, H. Tian, Circular RNA circTRPS1-2 inhibits the proliferation and migration of esophageal squamous cell carcinoma by reducing the production of ribosomes, *Cell Death Discov* 9 (2023) 5. 10.1038/s41420-023-01300-9.

101. L. Chen, R. Kong, C. Wu, S. Wang, Z. Liu, S. Liu, S. Li, T. Chen, C. Mao, S. Liu, Circ-MALAT1 Functions as Both an mRNA Translation Brake and a microRNA Sponge to Promote Self-Renewal of Hepatocellular Cancer Stem Cells, *Adv Sci (Weinh)* 7 (2020) 1900949. 10.1002/advs.201900949.
102. Y. Qin, Y. Zheng, C. Huang, Y. Li, M. Gu, Q. Wu, Knockdown of circSMAD2 inhibits the tumorigenesis of gallbladder cancer through binding with eIF4A3, *BMC Cancer* 21 (2021) 1172. 10.1186/s12885-021-08895-1.
103. B.R. Nelson, C.A. Makarewich, D.M. Anderson, B.R. Winders, C.D. Troupes, F. Wu, A.L. Reese, J.R. McAnally, X. Chen, E.T. Kavalali, S.C. Cannon, S.R. Houser, R. Bassel-Duby, E.N. Olson, A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle, *Science* 351 (2016) 271-275. 10.1126/science.aad4076.
104. C. Zhang, X. Yi, M. Hou, Q. Li, X. Li, L. Lu, E. Qi, M. Wu, L. Qi, H. Jian, Z. Qi, Y. Lv, X. Kong, M. Bi, S. Feng, H. Zhou, The landscape of m(1)A modification and its posttranscriptional regulatory functions in primary neurons, *Elife* 12 (2023). 10.7554/eLife.85324.
105. A.D. Perenkov, A.D. Sergeeva, M.V. Vedunova, D.V. Krysko, In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future, *Vaccines (Basel)* 11 (2023). 10.3390/vaccines11101600.
106. D. Huang, X. Zhu, S. Ye, J. Zhang, J. Liao, N. Zhang, X. Zeng, J. Wang, B. Yang, Y. Zhang, L. Lao, J. Chen, M. Xin, Y. Nie, P.E. Saw, S. Su, E. Song, Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides, *Nature* 625 (2024) 593-602. 10.1038/s41586-023-06834-7.
107. M. Li, Y. Wang, P. Wu, S. Zhang, Z. Gong, Q. Liao, C. Guo, F. Wang, Y. Li, Z. Zeng, Q. Yan, W. Xiong, Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy, *Cancer Lett* 563 (2023) 216190. 10.1016/j.canlet.2023.216190.
108. J. Xia, S. Li, B. Ren, P. Zhang, Circular RNAs as a potential source of neoepitopes in cancer, *Front Oncol* 13 (2023) 1098523. 10.3389/fonc.2023.1098523.
109. S.S. Titze-de-Almeida, R. Titze-de-Almeida, Progress in circRNA-Targeted Therapy in Experimental Parkinson's Disease, *Pharmaceutics* 15 (2023). 10.3390/pharmaceutics15082035.
110. A.C. Palcau, R. Brandi, N.H. Mehterov, C. Botti, G. Blandino, C. Pulito, Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment, *Cancers (Basel)* 15 (2023). 10.3390/cancers15164181.
111. Y.C. Lin, Y.C. Wang, Y.C. Lee, H.H. Lin, K.L. Chang, Y.C. Tai, K.Y. Hsiao, CircVIS: a platform for circRNA visual presentation, *BMC Genomics* 22 (2022) 921. 10.1186/s12864-022-08650-1.
112. Y. Chen, L. Yao, Y. Tang, J.H. Jhong, J. Wan, J. Chang, S. Cui, Y. Luo, X. Cai, W. Li, Q. Chen, H.Y. Huang, Z. Wang, W. Chen, T.H. Chang, F. Wei, T.Y. Lee, H.D. Huang, CircNet 2.0: an updated database for exploring circular RNA regulatory networks in cancers, *Nucleic Acids Res* 50 (2022) D93-D101. 10.1093/nar/gkab1036.
113. W. Zhang, Y. Liu, Z. Min, G. Liang, J. Mo, Z. Ju, B. Zeng, W. Guan, Y. Zhang, J. Chen, Q. Zhang, H. Li, C. Zeng, Y. Wei, G.C. Chan, circMine: a comprehensive database to integrate, analyze and visualize human disease-related circRNA transcriptome, *Nucleic Acids Res* 50 (2022) D83-D92. 10.1093/nar/gkab809.
114. D. Yao, L. Zhang, M. Zheng, X. Sun, Y. Lu, P. Liu, Circ2Disease: a manually curated database of experimentally validated circRNAs in human disease, *Sci Rep* 8 (2018) 11018. 10.1038/s41598-018-29360-3.
115. X. Ju, Y. Tang, R. Qu, S. Hao, The Emerging Role of Circ-SHPRH in Cancer, *Onco Targets Ther* 14 (2021) 4177-4188. 10.2147/OTT.S317403.
116. M. Zhang, N. Huang, X. Yang, J. Luo, S. Yan, F. Xiao, W. Chen, X. Gao, K. Zhao, H. Zhou, Z. Li, L. Ming, B. Xie, N. Zhang, A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis, *Oncogene* 37 (2018) 1805-1814. 10.1038/s41388-017-0019-9.
117. Y. Yang, X. Gao, M. Zhang, S. Yan, C. Sun, F. Xiao, N. Huang, X. Yang, K. Zhao, H. Zhou, S. Huang, B. Xie, N. Zhang, Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis, *J Natl Cancer Inst* 110 (2018) 304-315. 10.1093/jnci/djx166.
118. K. Li, Z.Y. Peng, R. Wang, X. Li, N. Du, D.P. Liu, J. Zhang, Y.F. Zhang, L. Ma, Y. Sun, S.C. Tang, H. Ren, Y.P. Yang, X. Sun, Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7, *Mol Cancer* 22 (2023) 103. 10.1186/s12943-023-01811-0.

119. S. Zhong, H. Xu, D. Wang, S. Yang, H. Li, H. Zhang, J. Feng, S. Zhou, circNFIB decreases synthesis of arachidonic acid and inhibits breast tumor growth and metastasis, *Eur J Pharmacol* 963 (2024) 176221. 10.1016/j.ejphar.2023.176221.
120. I. Legnini, G. Di Timoteo, F. Rossi, M. Morlando, F. Briganti, O. Sthandier, A. Fatica, T. Santini, A. Andronache, M. Wade, P. Laneve, N. Rajewsky, I. Bozzoni, Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis, *Mol Cell* 66 (2017) 22-37 e29. 10.1016/j.molcel.2017.02.017.
121. J. Zhong, X. Wu, Y. Gao, J. Chen, M. Zhang, H. Zhou, J. Yang, F. Xiao, X. Yang, N. Huang, H. Qi, X. Wang, F. Bai, Y. Shi, N. Zhang, Circular RNA encoded MET variant promotes glioblastoma tumorigenesis, *Nat Commun* 14 (2023) 4467. 10.1038/s41467-023-40212-1.
122. S. Zhang, C. Wang, Y. Wang, H. Zhang, C. Xu, Y. Cheng, Y. Yuan, J. Sha, X. Guo, Y. Cui, A novel protein encoded by circRsrc1 regulates mitochondrial ribosome assembly and translation during spermatogenesis, *BMC Biol* 21 (2023) 94. 10.1186/s12915-023-01597-z.
123. R. Chen, T. Yang, B. Jin, W. Xu, Y. Yan, N. Wood, H.I. Lehmann, S. Wang, X. Zhu, W. Yuan, H. Chen, Z. Liu, G. Li, T.S. Bowen, J. Li, J. Xiao, CircTmeff1 Promotes Muscle Atrophy by Interacting with TDP-43 and Encoding A Novel TMEFF1-339aa Protein, *Adv Sci (Weinh)* 10 (2023) e2206732. 10.1002/advs.202206732.
124. T. Mookherjee, A. Bagchi, R. Ghosh, In-silico studies to analyse the possible interactions of CircPPP1R12A translated peptide with Mst proteins, *Biochem Biophys Res Commun* 635 (2022) 108-113. 10.1016/j.bbrc.2022.10.006.
125. F. Hu, Y. Peng, S. Chang, X. Luo, Y. Yuan, X. Zhu, Y. Xu, K. Du, Y. Chen, S. Deng, F. Yu, X. Feng, X. Fan, H. Ashktorab, D. Smoot, S.J. Meltzer, S. Li, Y. Wei, X. Zhang, Z. Jin, Vimentin binds to a novel tumor suppressor protein, GSPT1-238aa, encoded by circGSPT1 with a selective encoding priority to halt autophagy in gastric carcinoma, *Cancer Lett* 545 (2022) 215826. 10.1016/j.canlet.2022.215826.
126. L. Wang, J. Zhou, C. Zhang, R. Chen, Q. Sun, P. Yang, C. Peng, Y. Tan, C. Jin, T. Wang, J. Ji, Y. Sun, A novel tumour suppressor protein encoded by circMAPK14 inhibits progression and metastasis of colorectal cancer by competitively binding to MKK6, *Clin Transl Med* 11 (2021) e613. 10.1002/ctm2.613.
127. Z.X. Liang, H.S. Liu, L. Xiong, X. Yang, F.W. Wang, Z.W. Zeng, X.W. He, X.R. Wu, P. Lan, A novel NF-kappaB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation, *Mol Cancer* 20 (2021) 103. 10.1186/s12943-021-01404-9.
128. W.C. Liang, C.W. Wong, P.P. Liang, M. Shi, Y. Cao, S.T. Rao, S.K. Tsui, M.M. Waye, Q. Zhang, W.M. Fu, J.F. Zhang, Translation of the circular RNA circbeta-catenin promotes liver cancer cell growth through activation of the Wnt pathway, *Genome Biol* 20 (2019) 84. 10.1186/s13059-019-1685-4.
129. W. Zhao, Y. Zhang, Y. Zhu, Circular RNA circbeta-catenin aggravates the malignant phenotype of non-small-cell lung cancer via encoding a peptide, *J Clin Lab Anal* 35 (2021) e23900. 10.1002/jcla.23900.
130. D. Mo, X. Li, C.A. Raabe, T.S. Rozhdestvensky, B.V. Skryabin, J. Brosius, Circular RNA Encoded Amyloid Beta peptides-A Novel Putative Player in Alzheimer's Disease, *Cells* 9 (2020). 10.3390/cells9102196.
131. Z. Pan, J. Cai, J. Lin, H. Zhou, J. Peng, J. Liang, L. Xia, Q. Yin, B. Zou, J. Zheng, L. Qiao, L. Zhang, A novel protein encoded by circFND3B inhibits tumor progression and EMT through regulating Snail in colon cancer, *Mol Cancer* 19 (2020) 71. 10.1186/s12943-020-01179-5.
132. D. Mo, X. Li, C.A. Raabe, D. Cui, J.F. Vollmar, T.S. Rozhdestvensky, B.V. Skryabin, J. Brosius, A universal approach to investigate circRNA protein coding function, *Sci Rep* 9 (2019) 11684. 10.1038/s41598-019-48224-y.
133. W.W. Du, J. Xu, W. Yang, N. Wu, F. Li, L. Zhou, S. Wang, X. Li, A.T. He, K.Y. Du, K. Zeng, J. Ma, J. Lyu, C. Zhang, C. Zhou, K. Maksimovic, B.B. Yang, A Neuroligin Isoform Translated by circNlgn Contributes to Cardiac Remodeling, *Circ Res* 129 (2021) 568-582. 10.1161/CIRCRESAHA.120.318364.
134. Y. Peng, Y. Xu, X. Zhang, S. Deng, Y. Yuan, X. Luo, M.T. Hossain, X. Zhu, K. Du, F. Hu, Y. Chen, S. Chang, X. Feng, X. Fan, H. Ashktorab, D. Smoot, S.J. Meltzer, G. Hou, Y. Wei, S. Li, Y. Qin, Z.

- Jin, A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/beta-catenin signaling pathway to promote gastric cancer progression, *Mol Cancer* 20 (2021) 158. 10.1186/s12943-021-01457-w.
135. Y. Li, Z. Wang, P. Su, Y. Liang, Z. Li, H. Zhang, X. Song, D. Han, X. Wang, Y. Liu, J. Yang, B. Chen, L. Wang, W. Zhao, Q. Yang, circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway, *Mol Ther* 30 (2022) 415-430. 10.1016/j.ymthe.2021.08.026.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.